Summary

for people ages 12 months to 21 years (full criteria)
at San Francisco, California and other locations
study started
estimated completion

Description

Summary

The main purpose of this study is to evaluate the safety of the study drug known as ramucirumab in children with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Official Title

A Phase 1 Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors

Keywords

Pediatric Solid TumorRefractory TumorRecurrent TumorCNS Malignanciesrelapsed pediatric solid tumorsunspecified childhood solid tumorbrain and central nervous system tumorsNeoplasmsEndothelial Growth FactorsRamucirumab

Eligibility

You can join if…

Open to people ages 12 months to 21 years

  • Part A: participants with recurrent or refractory non-CNS solid tumors
  • Part B: participants with recurrent or refractory CNS tumors
  • Measurable or evaluable disease
  • No other therapeutic options
  • Performance Status: Karnofsky ≥50% for participants >16 years and Lansky ≥50 for participants ≤16 years

You CAN'T join if...

  • Active or recent history of serious bleeding events
  • Active or recent history of gastrointestinal perforations, ulcers, fistulas or abscesses
  • Active or recent history of hypertensive crisis or hypertensive encephalopathy
  • Active non-healing wound or bone fracture
  • History of solid organ transplant

Locations

  • University of California, San Franciscoaccepting new patients
    San FranciscoCalifornia94158United States
  • Children's Oncology Groupaccepting new patients
    MonroviaCalifornia91016United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
more information about this study: A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors
ID
NCT02564198
Phase
Phase 1
Study Type
Interventional
Last Updated